E
EDAP TMS S.A.
Biotechnology: Electromedical & Electrotherapeutic Apparatus company
Key Metrics of EDAP TMS S.A.
Revenue—FY 2023
Operating income—
Net profit—
Shareholders' equity$62.9M
Market cap$189MFOCL · $4.12
Competitors10identified
About EDAP TMS S.A.
Sectors
Company details
- Listed
- Nasdaq: FOCL
Operational Areas of EDAP TMS S.A.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameEDAP TMS S.A.
TickerFOCL
ExchangeNasdaq
CountryFrance
SEC CIK0001041934
Listed since—
IndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
FOCL · Nasdaq · SEC CIK 0001041934
Last price · 29 Oct 2026
$4.12
−2.60%
Market cap$189M
P/E—On FY 2023 diluted EPS
Volume10,197
SectorHealth CareBiotechnology: Electromedical & Electrotherapeutic Apparatus
Country · IPOFrance
FOCL share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of EDAP TMS S.A.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.